10 hours ago
Blood Plasma Market to Witness Strong Growth at 10.8% CAGR, Expected to Hit USD 79.5 Mn by 2032
The trend in the blood plasma industry is characterized by a growing focus on research and development activities to develop novel plasma-derived therapies, increasing collaboration between plasma collection centers and pharmaceutical companies, and the expansion of plasma collection networks worldwide. Additionally, there is a growing emphasis on improving the safety and quality of plasma-derived products through stringent regulatory guidelines and advanced testing methodologies.
Blood Plasma Market Insights
The blood plasma industry has witnessed robust expansion driven by rising therapeutic demand and advanced manufacturing processes. Experts leverage novel fractionation techniques to meet growing immunoglobulin and albumin requirements, reflecting deep market research and market insights underpinning strategic decisions.
The Global Blood Plasma Market size is estimated to be valued at USD 38.8 Mn in 2025 and is expected to reach USD 79.5 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 10.8% from 2025 to 2032.
Market Key Takeaways
- Region:
- North America: robust regulatory framework and extensive donor networks enhance plasma availability.
- Latin America: emerging collection centers in Brazil and Argentina drive capacity expansion.
- Europe: strategic investments in fractionation plants support product diversification.
- Asia Pacific: growing haemophilia treatment demand in China and India fuels capacity uptake.
- Middle East: increasing collaborations improve regional self‐sufficiency in plasma derivatives.
- Africa: pilot programs in South Africa strengthen plasma collection infrastructure.
- Segment Covers:
- Product Type:
• Immunoglobulins: high‐volume IVIG therapies for autoimmune disorders.
• Albumin: critical care applications in shock treatment.
• Clotting Factors: haemophilia A and B management solutions.
- Application:
• Therapeutics: replacement therapies in immunodeficiency syndromes.
• Diagnostics: plasma‐derived reagents for transfusion testing.
- End‐User:
• Hospitals: primary consumers of albumin and clotting factor concentrates.
• Specialty Clinics: immunoglobulin administrations for chronic conditions.
Growth Factors:
Rising prevalence of immunodeficiency disorders and expanded market scope into recombinant fractions are key market drivers. Global immunoglobulin consumption reached 1,400 tons in 2024, up 8% year-on-year, offering significant market opportunities. Voluntary donor enrollment in North America surged 12% in 2024, driving a 7% uplift in collection volumes. Advanced fractionation capacity—such as the Octapharma Germany facility adding 50,000 L/month in mid-2024—bolstered supply. These drivers present market growth strategies alongside market challenges and restraints, supporting sustainable business growth and a projected 10.8% CAGR through 2032.
Book the Latest Edition of this Market Study Get Up to 25 % Discount:
Market Trends:
Recent market research and market insights reveal accelerated AI-enabled donor screening that reduced deferral rates by 15% in 2024, enhancing supply reliability. Consolidation with regional partners—illustrated by Grifols' 2025 alliance in China—drives consolidation-driven market share shifts. Custom nano-scale chromatography methods achieved a 5% yield gain over conventional fractionation. Pressure from donor deferrals remains a key market restraint, while technological differentiation and regional capacity localization continue to define Blood Plasma Market trends and industry trends.
Actionable Insights
• Production Capacity: 5.2 M L/month global plasma processing in 2024, supporting an estimated market revenue uplift of USD 2.5 Mn monthly.
• Pricing: IVIG average selling price at USD 90/g in Q4 2024, influencing overall market revenue stabilization.
• Exports: U.S. plasma exports rose 9% in H2 2024 to 300k L, boosting supplier revenues.
• Imports: EU plasma imports grew 11% in Q1 2025, reflecting demand-driven revenue influx.
• Use Cases: APAC hospital albumin usage grew 7% in 2024, expanding revenue streams in critical care.
• Micro-indicators: emerging nano-fractionation sites (
Key Players:
• CSL Behring
• Grifols
• Takeda Pharmaceutical (formerly Shire)
• Octapharma
• Kedrion Biopharma
• Bio Products Laboratory
• LFB Group
• Sanquin Plasma Products
• China Biologic Products
• ADMA Biologics
• GC Pharma
• CSL Plasma
• Emergent BioSolutions
• Kamada
• Centurion Pharma
Get Customization on this Report:
Competitive Strategies:
• CSL Behring's vertical integration of collection and fractionation in 2024 reduced COGS by 6% and improved margin by 2.3%.
• Grifols' alliance with Shandong Weigao expanded plasma centers by 15 sites in China, increasing Asian Blood Plasma Market share.
• Takeda's clinical partnerships with rare‐disease clinics in 2024 drove immunoglobulin adoption, boosting U.S. market revenue by 5%.
• Kedrion Biopharma's targeted partnerships elevated its industry share among emerging biopharma companies by 3% in 2024.
Frequently Asked Questions
1. Who are the dominant players in the Blood Plasma Market?
Key players include CSL Behring, Grifols, Takeda, Octapharma, Kedrion Biopharma and others that account for major technological and capacity leadership.
2. What will be the size of the Blood Plasma Market in the coming years?
The Blood Plasma Market size is projected to grow from USD 38.8 Mn in 2025 to USD 79.5 Mn by 2032 at a 10.8% CAGR.
3. Which end-user industry has the largest growth opportunity?
Hospitals and specialty clinics administering IVIG and clotting factors for immunodeficiency and haemophilia represent the largest growth segments.
4. How will market development trends evolve over the next five years?
Trends include AI-driven donor screening, nano-scale fractionation, and regional capacity localization as per the latest Blood Plasma Market report.
5. What is the nature of the competitive landscape and challenges in the Blood Plasma Market?
The landscape remains consolidated, with key players pursuing vertical integration, regional alliances and facing donor-recruitment challenges as primary market restraints.
6. What go-to-market strategies are commonly adopted in the Blood Plasma Market?
Strategies include strategic partnerships for capacity expansion, targeted clinical collaborations, differentiated fractionation technologies and localized regulatory approvals to drive market opportunities.
About Coherent Market Insights
Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
